San Francisco-based Ideaya Biosciences on Tuesday said that it has dosed its first uveal melanoma patient in a clinical trial evaluating its PKC inhibitor IDE196 with Pfizer’s cMET inhibitor crizotinib (Xalkori).
Archive | Health Professionals
Ideaya Biosciences Begins Trial of IDE196, Xalkori in Uveal Melanoma Patients
Posted in Melanoma News, Health Professionals, Clinical Trials
Texas A&M Research Explores How Melanoma Grows And Spreads
The first step in treating cancer is understanding how it starts, grows and spreads throughout the body.
Posted in Melanoma News, Health Professionals, Of Interest
Ultraviolet radiation causes rare type of eye cancer
Ultraviolet radiation can cause a rare type of eye cancer, conjunctival melanoma, according to University of Manchester research funded by Cancer Research UK and others* and published** in Nature Communications today (Monday).
Posted in Melanoma News, Health Professionals, Of Interest
Advanced humanized mouse model helps better understand immunotherapy resistance in melanoma
Scientists at The Wistar Institute have created an advanced humanized immune system mouse model that allows them to examine resistance to immune checkpoint blockade therapies in melanoma.
Posted in Melanoma News, Health Professionals, Of Interest
